|
Name |
Cyclopropa[d]naphthalen-3(1H)-one, octahydro-2,4a,8,8-tetramethyl-, (1aS,2S,4aS,8aS)-
|
Molecular Formula | C15H24O | |
IUPAC Name* |
(1aS,2S,4aS,8aS)-2,4a,8,8-tetramethyl-1a,2,4,5,6,7-hexahydro-1H-cyclopropa[j]naphthalen-3-one
|
|
SMILES |
C[C@H]1[C@@H]2C[C@]23[C@@](CCCC3(C)C)(CC1=O)C
|
|
InChI |
InChI=1S/C15H24O/c1-10-11-8-15(11)13(2,3)6-5-7-14(15,4)9-12(10)16/h10-11H,5-9H2,1-4H3/t10-,11-,14-,15-/m0/s1
|
|
InChIKey |
LFWRAJWJODKLTN-GVARAGBVSA-N
|
|
Synonyms |
3-Thujopsanone; 25966-79-4; Cyclopropa[d]naphthalen-3(1H)-one, octahydro-2,4a,8,8-tetramethyl-, (1aS,2S,4aS,8aS)-; Cyclopropa(d)naphthalen-3(1H)-one, octahydro-2,4a,8,8-tetramethyl-, (1aS,2S,4aS,8aS)-; (-)-Thujopsanone; EINECS 247-381-1; SCHEMBL20024360; DTXSID70885321; Q67879579; (1aS,8aS)-Octahydro-2alpha,4abeta,8,8-tetramethylcyclopropa[d]naphthalen-3(1H)-one; (1AS-(1aalpha,2alpha,4abeta,8aR*))-octahydro-2,4a,8,8-tetramethylcyclopropa(d)naphthalen-3(1H)-one
|
|
CAS | 25966-79-4 | |
PubChem CID | 13893399 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 220.35 | ALogp: | 4.2 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 17.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.588 |
Caco-2 Permeability: | -4.745 | MDCK Permeability: | 0.00001830 |
Pgp-inhibitor: | 0.035 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.177 |
30% Bioavailability (F30%): | 0.849 |
Blood-Brain-Barrier Penetration (BBB): | 0.842 | Plasma Protein Binding (PPB): | 79.60% |
Volume Distribution (VD): | 1.085 | Fu: | 29.92% |
CYP1A2-inhibitor: | 0.151 | CYP1A2-substrate: | 0.693 |
CYP2C19-inhibitor: | 0.281 | CYP2C19-substrate: | 0.931 |
CYP2C9-inhibitor: | 0.273 | CYP2C9-substrate: | 0.228 |
CYP2D6-inhibitor: | 0.022 | CYP2D6-substrate: | 0.218 |
CYP3A4-inhibitor: | 0.773 | CYP3A4-substrate: | 0.61 |
Clearance (CL): | 17.058 | Half-life (T1/2): | 0.12 |
hERG Blockers: | 0.057 | Human Hepatotoxicity (H-HT): | 0.451 |
Drug-inuced Liver Injury (DILI): | 0.079 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.953 | Maximum Recommended Daily Dose: | 0.373 |
Skin Sensitization: | 0.318 | Carcinogencity: | 0.955 |
Eye Corrosion: | 0.651 | Eye Irritation: | 0.513 |
Respiratory Toxicity: | 0.966 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001080 | 0.500 | D0H1QY | 0.286 | ||||
ENC002143 | 0.500 | D0L2LS | 0.271 | ||||
ENC003100 | 0.458 | D0Z1XD | 0.268 | ||||
ENC001322 | 0.433 | D0U3GL | 0.268 | ||||
ENC003051 | 0.424 | D0Q6NZ | 0.267 | ||||
ENC003477 | 0.410 | D0I2SD | 0.261 | ||||
ENC003049 | 0.381 | D09NNA | 0.250 | ||||
ENC001810 | 0.381 | D04SFH | 0.247 | ||||
ENC001193 | 0.361 | D04GJN | 0.247 | ||||
ENC001452 | 0.353 | D0IX6I | 0.239 |